Vimta Labs Limited (IN:VIMTALABS)
:VIMTALABS
Want to see IN:VIMTALABS full AI Analyst Report?
Top Page
Vimta Labs Limited
(VIMTALABS)
Select Model
Select Model
Rating:74Outperform
Price Target:
₹576.00
▼(-5.46% Downside)
Action:Reiterated
Date:06/04/26
The score is primarily supported by strong financial quality—especially a very low-leverage balance sheet and healthy profitability—offset by less attractive valuation (high P/E and low dividend yield). Technicals are moderately positive (above key shorter-term averages with positive MACD) but tempered by stretched momentum indicators and trading below the 200-day average.
Positive Factors
Conservative Balance Sheet
Very low leverage and rising equity materially reduce financial risk and preserve strategic optionality. This balance-sheet strength supports capex for lab capacity, tolerates cyclic demand swings in outsourced testing, and lowers refinancing pressure over the medium term.
Negative Factors
Margin Volatility
Material swings in gross and operating margins suggest exposure to mix shifts, pricing pressure or cost variability. Persistent volatility reduces earnings predictability, complicates capital allocation and raises execution risk for sustaining long-term margin targets.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low leverage and rising equity materially reduce financial risk and preserve strategic optionality. This balance-sheet strength supports capex for lab capacity, tolerates cyclic demand swings in outsourced testing, and lowers refinancing pressure over the medium term.
Read all positive factors
Vimta Labs Limited (VIMTALABS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹23.27B
Dividend Yield0.16%
Average Volume (3M)22.50K
Price to Earnings (P/E)30.0
Beta (1Y)1.07
Revenue Growth16.08%
EPS Growth14.59%
CountryIN
Employees1,428
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)17.65
Shares Outstanding44,669,353
10 Day Avg. Volume11,086
30 Day Avg. Volume22,501
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)3.71
Price to Sales (P/S)4.16
P/FCF Ratio34.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)20.1
Revenue Forecast (FY)₹4.71B
Vimta Labs Limited Business Overview & Revenue Model
Company Description
Vimta Labs Limited provides specialized contract research and analytical testing services, operating both within India and internationally. Their extensive offerings encompass general laboratory analyses, comprehensive food and water quality testi...
How the Company Makes Money
Vimta Labs makes money by providing fee-based outsourced services to customers that need laboratory testing and clinical/medical research work performed under applicable quality and regulatory frameworks. Its core revenue streams typically include...
Vimta Labs Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.84B | 4.07B | 3.44B | 3.18B | 3.15B | 2.76B |
| Gross Profit | 2.32B | 1.68B | 1.33B | 2.42B | 2.41B | 914.08M |
| EBITDA | 1.41B | 1.42B | 1.26B | 902.01M | 966.38M | 802.74M |
| Net Income | 786.29M | 775.12M | 673.42M | 410.09M | 481.72M | 413.30M |
Balance Sheet | ||||||
| Total Assets | 5.18B | 5.62B | 4.67B | 4.00B | 3.62B | 3.07B |
| Cash, Cash Equivalents and Short-Term Investments | 564.64M | 670.61M | 327.21M | 256.01M | 395.73M | 112.06M |
| Total Debt | 67.97M | 33.32M | 85.15M | 191.89M | 149.88M | 193.41M |
| Total Liabilities | 1.02B | 1.05B | 876.84M | 803.54M | 805.39M | 732.14M |
| Stockholders Equity | 4.16B | 4.57B | 3.79B | 3.20B | 2.82B | 2.34B |
Cash Flow | ||||||
| Free Cash Flow | 270.48M | 489.82M | 157.66M | -156.78M | 381.32M | 203.45M |
| Operating Cash Flow | 748.73M | 1.49B | 948.30M | 608.92M | 879.37M | 590.69M |
| Investing Cash Flow | -558.92M | -1.32B | -755.37M | -760.48M | -572.56M | -378.48M |
| Financing Cash Flow | -66.76M | -98.43M | -166.81M | -19.03M | -109.81M | -166.14M |
Vimta Labs Limited Technical Analysis
Positive
609.25
Price Trends
467.58
Positive
465.62
Positive
569.64
Negative
Market Momentum
16.80
Negative
62.86
Neutral
68.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIMTALABS, the sentiment is Positive. The current price of 609.25 is above the 20-day moving average (MA) of 480.42, above the 50-day MA of 467.58, and above the 200-day MA of 569.64, indicating a neutral trend. The MACD of 16.80 indicates Negative momentum. The RSI at 62.86 is Neutral, neither overbought nor oversold. The STOCH value of 68.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VIMTALABS.
Vimta Labs Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹267.17B | 52.73 | ― | 0.89% | 12.25% | 3.57% | |
74 Outperform | ₹23.27B | 30.02 | ― | 0.16% | 16.08% | 14.59% | |
73 Outperform | ₹82.75B | 50.18 | ― | 0.68% | 20.61% | 77.73% | |
72 Outperform | ₹107.75B | 56.64 | ― | 0.21% | 23.64% | 29.96% | |
71 Outperform | ₹131.36B | 76.17 | ― | 0.20% | 19.49% | 20.50% | |
55 Neutral | ₹17.25B | 17.05 | ― | 0.38% | 7.75% | 30.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:VIMTALABS
Vimta Labs Limited
521.05
17.95
3.57%
IN:KRSNAA
Krsnaa Diagnostics Limited
531.90
-143.88
-21.29%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,593.75
118.85
8.06%
IN:METROPOLIS
Metropolis Healthcare Ltd.
519.70
84.51
19.42%
IN:THYROCARE
Thyrocare Technologies Ltd
519.90
198.72
61.87%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,278.75
321.63
33.60%
Vimta Labs Limited Corporate Events
Vimta Labs moves to clean up shareholder records as IEPF transfers, KYC drive and special demat window advance
Apr 28, 2026
Vimta Labs has notified shareholders that unclaimed final dividends for FY 2018-19 and the corresponding equity shares will be transferred to the Investor Education and Protection Fund if not claimed by the statutory deadline, with detailed shareh...
Vimta Labs Reschedules Analyst Meet, Adds New Investor Interaction
Mar 27, 2026
Vimta Labs Limited has informed the stock exchanges that an analyst and institutional investor meeting originally scheduled for March 27, 2026 has been rescheduled to March 31, 2026, with a one-on-one online meeting set with Valcore Capital in the...
Vimta Labs Reschedules Analyst Meet, Adds New Investor Interaction
Mar 27, 2026
Vimta Labs Limited has rescheduled a previously planned analyst and institutional investor meeting, moving it to March 31, 2026, for a one-on-one online session with Valcore Capital. The company also added a new one-on-one online meeting with CVC ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.